We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01460641
Recruitment Status : Completed
First Posted : October 27, 2011
Last Update Posted : September 7, 2018
Information provided by (Responsible Party):
Aya Kamaya, Stanford University

Brief Summary:
A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.

Condition or disease
Rectal Cancer

Detailed Description:
Recent advances in computed tomography (CT) technology have made CT perfusion imaging feasible for the assessment of tumor perfusion in solid tumors of the abdomen. CT perfusion has shown promising results in serving as a noninvasive method of predicting response to therapy in cancer patients. CT perfusion parameters have also been found to correlate with immunohistologic markers of angiogenesis in a number of solid tumors, suggesting a possible role for CT perfusion as a noninvasive biomarker of tumor angiogenesis. The goals of the investigators study are twofold: first, to determine the relationship between baseline CT perfusion characteristics of rectal cancers and their response to treatment, and second, to determine if perfusion CT can be used to subsequently monitor tumor response to treatment. The investigators hope to enroll those patients with locally advanced rectal cancer undergoing standard CT for pre-treatment planning, integrating CT perfusion imaging into the current abdomen/pelvis imaging protocol with close clinical and radiologic follow-up after treatment to determine response to therapy and time to disease progression.

Layout table for study information
Study Type : Observational
Actual Enrollment : 21 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
Study Start Date : November 2011
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2018

CT perfusion

Primary Outcome Measures :
  1. Tumor stage change from Computed Tomography (CT) perfusion measurement [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Tumor perfusion as measured by perfusion CT. [ Time Frame: 1 year ]

Biospecimen Retention:   Samples With DNA
If the patient undergoes surgery to remove the lesion in the rectum, the surgical specimen will be examined by the pathologist, who will perform a variety of tests to detect evidence of new blood vessel growth. The sample will be stored per routine protocol of the Stanford Department of Pathology.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with locally advanced rectal cancer undergoing standard CT for pre-treatment planning

Inclusion Criteria:

  • Patients with suspected or biopsy-proven, locally advanced rectal cancer will be eligible for enrollment.
  • Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant.
  • No life expectancy restrictions.
  • ECOG and Karnofsky Performance Status will not be employed.
  • Patients with renal failure are ineligible for this study (GFR must be > 60)
  • Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients who have undergone prior treatment for rectal cancer are ineligible for enrollment.
  • No restrictions regarding use of other investigational agents.
  • Patients with severe contrast allergy are ineligible.
  • Patients who are pregnant or are trying to become pregnant are excluded from this study.
  • Patients who are cancer survivors or HIV-positive will not be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01460641

Layout table for location information
United States, California
Stanford University, School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Layout table for investigator information
Principal Investigator: Aya Kamaya Stanford University
Layout table for additonal information
Responsible Party: Aya Kamaya, Associate Professor of Radiology, Stanford University
ClinicalTrials.gov Identifier: NCT01460641    
Other Study ID Numbers: REC0006
SU-10202011-8538 ( Other Identifier: Stanford University )
19224 ( Other Identifier: Stanford IRB )
First Posted: October 27, 2011    Key Record Dates
Last Update Posted: September 7, 2018
Last Verified: September 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases